Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB

1.09%

92.5¢ mesoblast limited

CEO Itescu needs to go, page-627

First 627 Last

Share
Profile

Follow
Pupafly

211 Posts.

41

16/08/23

10:55

Post #: 69365733
Share

Originally posted by dolcevita: ↑

These are good points:

IF the FDA had a deep-seated problem with CMC issues, which they did express during the ODAC hearing, why did they empanel a committee of experts to vote on efficacy in the first place??

The potency assay issue should have been picked up in the rolling submission or addressed before going to the trouble of an ODAC hearing.

In essence, FDA said, "We're not sure the product can be made in a uniformly potent fashion... but please give us a vote on efficacy of a product we can't be sure is made with uniform potency. That's nonsensical. Most likely answer is bureaucratic inefficiency (as opposed to corruption).

These are illustrating the statements I'm making about inconsistency and capriciousness of the FDA.

So SI and team have come back to them on assays and consistency in the expectation that is the remaining barriers to approval and they raise more issues and decide that they won't require double blind study on children but they will on adults.

What is the reasoning? This goes to policy, that must underpin the decisions and the criteria for making those decisions.
More importantly, why did they ignore the 9-1 vote on efficacy in children, and why did they not revert to this recommendation on efficacy once those additional manufacturing and assay requirements were met?

I also agree where there is confusion there is often incompetence and this should be suspected first, but you cannot exclude corruption entirely. If people speculate about corruption it is a valid matter to consider especially if there is an apparent conflict of interest in the dissenting vote of the ODAC. It's not as if the FDA is entirely consistent, ethical and transparent in all actions is it? So I think some healthy scepticism is in order.

it's difficult to avoid the conclusion that the FDA is casting around and requiring levels of scrutiny it did not previously require and also would not require of pharmaceutical drugs because they have an established model. The latter is not necessarily more efficient or more valid.

They are messing around with MSB and it's sensible to fully explore this before jumping to conclusions that supposedly, 'SI needs to go'.

This is what I meant by damaging emotional reactions. And that damage has been done. The thread needs to die but it won't because the originators want to feed it and we have to respond to that. So it's constantly putting out spot fires and trying to shift the focus not easy when so many fires have been lit.

Expand

Why are we still debating the 9 to 1 decision. It is done and dusted let us move on. Such things may happen again. Is there anything we can do should it happen again. If so let us discuss

MSB Price at posting: 37.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Revolutionary inverter technology leads the clean energy charge

Exploring the causes and potential solutions to Australia's housing crisis

PV1

Provaris tells ASX non-binding MOUs are still material to share prices in somewhat fiery compliance response

Emerald & Azure score Digger & Dealer awards

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

There are more pages in this discussion • 281 more messages in this thread...

First 627 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 92.5¢		Change 0.010(1.09%)		Mkt cap ! $1.056B

Open	High	Low	Value	Volume
90.5¢	94.0¢	89.5¢	$4.970M	5.436M

Buyers (Bids)

No.	Vol.	Price($)
1	18877	92.0¢

Sellers (Offers)

Price($)	Vol.	No.
92.5¢	6795	1

View Market Depth

No.	Vol.	Price($)
1	18877	0.920
4	57615	0.915
4	170707	0.910
5	132198	0.905
6	205763	0.900

Price($)	Vol.	No.
0.925	6795	1
0.930	37503	3
0.935	49349	3
0.940	161756	6
0.945	29349	1

Last trade - 16.10pm 08/08/2024 (20 minute delay)

MSB (ASX) Chart

CEO Itescu needs to go, page-627

Revolutionary inverter technology leads the clean energy charge

Exploring the causes and potential solutions to Australia's housing crisis

Provaris tells ASX non-binding MOUs are still material to share prices in somewhat fiery compliance response

Emerald & Azure score Digger & Dealer awards

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

CEO Itescu needs to go, page-627

Top Stories

Revolutionary inverter technology leads the clean energy charge

Exploring the causes and potential solutions to Australia's housing crisis

Provaris tells ASX non-binding MOUs are still material to share prices in somewhat fiery compliance response

Emerald & Azure score Digger & Dealer awards

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News